(Q41678107)

7 October 2017

1 reference

title

Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I. (English)

1 reference

7 October 2017

Sandritter TL

1

1 reference

PubMed ID

9423415

7 October 2017

Kraus DM

series ordinal

2

1 reference

7 October 2017

1 November 1997

1 reference

Journal of Pediatric Health Care

7 October 2017

1 reference

7 October 2017

11

1 reference

7 October 2017

6

1 reference

7 October 2017

284-91; quiz 292-3

1 reference

A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus

7 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

A trial of RSV immune globulin in infants and young children: the FDA's view

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Deaths associated with respiratory tract infection in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Epidemiology of acute lower respiratory disease in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Modes of transmission of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Treatment and prevention options for respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Comparative virulence of respiratory syncytial virus subgroups A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5245%2897%2990086-9

7 January 2021

10.1016/S0891-5245(97)90086-9

Identifiers

DOI

1 reference

7 October 2017

1 reference

PubMed ID

9423415